Out of Stock

Retatrutide+

GLP-1 / GIP / Glucagon / Amylin Receptor Agonist Blend

RM 550

FormLyophilized Powder

Storage2-8°C

This product is currently out of stock and cannot be purchased.

Out of Stock

Retatrutide+ is an advanced next-generation metabolic compound combining Retatrutide — a triple GLP-1 / GIP / Glucagon receptor agonist — with a second proprietary component that targets the amylin receptor pathway. This dual-mechanism formulation represents one of the most comprehensive metabolic interventions available, simultaneously addressing appetite regulation, energy expenditure, glucose homeostasis, and satiety signaling through four complementary receptor systems. The result is a profoundly synergistic effect on weight loss, metabolic health, and cardiometabolic risk factors that surpasses any single-agent approach currently known.

Research Metrics

4xReceptors

Quad-receptor activation

30%Weight Loss

Max body weight reduction

≥99%Purity

HPLC verified

95%Bioavailability

Subcutaneous absorption

Mechanism of Action

Retatrutide provides triple agonism across GLP-1R, GIPR, and GcgR: GLP-1R activation enhances glucose-dependent insulin secretion and suppresses appetite; GIPR potentiates insulin response and supports fat redistribution; GcgR elevates energy expenditure through thermogenesis. The second proprietary component targets the amylin receptor complex (AMY1-3), independently suppressing glucagon secretion, slowing gastric emptying, reducing food intake through central satiety circuits, and modulating the mesolimbic reward system. The four-receptor synergy produces additive-to-synergistic effects on weight loss and metabolic parameters.

Scientific Benefits

Superior Weight Loss — Four-receptor synergy produces fat mass reductions with total body weight loss potential exceeding 25–30% in sustained protocols.
Prolonged Satiety & Appetite Suppression — The amylin receptor component extends and deepens appetite suppression initiated by GLP-1 activation over a longer post-meal window.
Reduced Food Reward and Cravings — Acts centrally to reduce the hedonic drive to eat, particularly blunting cravings for high-fat and high-sugar foods.
Enhanced Blood Glucose Control — GLP-1 and GIP activation improves insulin secretion; amylin pathway adds complementary glucose control by suppressing post-meal glucagon release.
Accelerated Fat Oxidation — Glucagon receptor agonism increases hepatic fat oxidation and raises basal metabolic rate across multiple tissues.
Visceral and Hepatic Fat Reduction — Both receptor pathways independently reduce visceral adipose tissue and hepatic fat accumulation (NAFLD/NASH).
Cardiovascular Risk Reduction — Amplified improvements in blood pressure, triglycerides, LDL cholesterol, HbA1c, and systemic inflammation markers.
Lean Mass Preservation — Weight loss occurs predominantly from fat mass; amylin component has shown preferential fat loss over lean tissue loss in research models.
Metabolic Syndrome Reversal — Addresses all five criteria of metabolic syndrome simultaneously: central obesity, elevated triglycerides, low HDL, hypertension, and hyperglycemia.

Disclaimer & Usage Notice

GENERAL USAGE NOTICE. The products offered on this website are sold strictly for your own personal purposes. By purchasing, you acknowledge that you are assuming all risks associated with the handling and application of these products.